Appropriate Regulation of Adjunctive Devices: Embolic Protection

Slides:

Advertisements

Similar presentations

FDA QS reg/CLIA Comparison: Overview

Advertisements

Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958 (FFDCA)

Regulatory Pathway for Platform Technologies

Safety Guidelines Illness and Injury Prevention Safety Guidelines Illness and Injury Prevention 2.01 Understand safety procedures 1.

"Determining the Regulatory Pathway to Market" Classification Heather S. Rosecrans Director, 510(k) Staff Office of Device Evaluation Center for Devices.

Advancing the Development of Pediatric Therapeutics (ADEPT) II: Evaluation of Long-term Neurocognitive Development in Pediatrics U.S. Food and Drug Administration.

FDA Update on Laboratory Developed Tests Oversight Laura M. St. Martin, M.D., M.P.H. Acting Branch Chief, Human Tissues and Reproduction Branch, Division.

Special Topics in IND Regulation

+ Medical Devices Approval Process. + Objectives Define a medical device Be familiar with the classification system for medical devices Understand the.

Center for Devices and Radiological Health U. S. Department of Health and Human Services Al Taylor Acting Chief, Medical Electronics Branch Office of Science.

Federal Food, Drug, and Cosmetic Act 1938, 1954, 1958 (FFDCA) Katie Buhai Period 3.

The Practical Art of Endpoint Selection: Industry Perspectives A View from the Pharma Industry of the FDA Guidance on PROs Glenn A. Phillips, Ph.D. Director.

Legal & Ethical Issues. Objectives At the completion of this session the participant will be able to: ◦ Describe the ethical principles associated with.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Trial Design Issues Associated with Evaluation of Distal Protection Devices in Diseased Saphenous Vein Grafts Bram D. Zuckerman, MD, FACC Medical Officer,

UPCOMING CHANGES TO IN-VITRO DIAGNOSTICS (IVDs) AND LABORATORY DEVELOPED TESTS (LDTs) REGULATIONS Moj Eram, PhD November 5, 2015.

CP CARE Registry Insights to the Future.

GU Advisory Panel Meeting Nocturnal Home Hemodialysis Draft Carolyn Y. Neuland, Ph.D. Chief, Gastroenterology and Renal Devices Branch Division of Reproductive,

Radiology Advisory Panel Meeting Radiology Advisory Panel Meeting Computer-Assisted Detection (CADe) Devices Joyce M. Whang Deputy Division Director Radiological.

Pediatric Drug Development: A Regulatory Perspective Tiffany R. Farchione, M.D. Medical Officer, Division of Psychiatry Products US Food and Drug Administration.

November 9, 2015 February 20, 2017 Using real world evidence – industry perspective Pma indication expansion Melissa hasenbank, phd Sr. Clinical Research.

Regulatory Requirements for Drug Eluting Balloons

CLI and Device Intervention Across the Pacific – An FDA View

Rachel Neubrander, PhD Division of Cardiovascular Devices

Use of Postmarket Data to Support Premarket Approvals

Clinical Review Process for New Drug Development and Application

What Are the FDA Requirements for Submitting an IDE?

Division of Cardiovascular Devices

Hina M. Pinto, MSE Scientific Reviewer

U.S. FDA Center for Devices and Radiological Health Update

Regulatory Considerations for Coronary Drug Coated Balloons (DCBs)

VenaSeal Closure System Utilization of the Pre-Submission Process & Interactive Review Sponsor’s Perspective 24 February 2015.

Adherence to the Labeling

FDA Pathway to Approval: Clinical Requirements for Renal Denervation

Premarket Notification 510(k) process

Jeff Shuren, MD, JD Center for Devices and Radiological Health U. S

Andrew Farb, MD and Dorothy Abel, BSBME

FDA’s IDE Decisions and Communications

Director, Asia Pacific Japan and U.S. Clinical Operations

Balancing Pre and Postmarket Requirements Different Scenarios

Balancing Regulation and Innovation: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Reasonable Assurance of Safety and Effectiveness: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division.

The FDA Early Feasibility Study Pilot and the Innovation Pathway

The Current PMA Requirements

Clinical Trials Medical Interventions

Calcified Lesion and Device Intervention Across the Pacific: PMDA View

Deputy Director, Division of Biostatistics No Conflict of Interest

Lessons Learned Through HBD: The Industry’s View

Introduction of New Technology: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Medical Device Regulatory Essentials: An FDA Division of Cardiovascular Devices Perspective Bram Zuckerman, MD, FACC Director, FDA Division of Cardiovascular.

Lessons Learned: Past Present and Future Japan-USA Regulatory Interactions Erica Takai, PhD US Food and Drug Administration

US Early Feasibility Studies (EFS)

Lessons Learned Through HBD: The Regulator’s View - US FDA

The FDA’s View on CTO-PCI Devices

Regulatory Considerations for Coronary Drug Coated Balloons – FDA View

FDA-CDRH in the Next Decade A Vision for Change

Erica Takai, PhD for Andrew Farb, M.D.

IRB – Human subjects research incoming staff orientation 2018

Streamlining IRB Procedures for Expanded Access

FDA Medical Device Approval Pathways

Safety Guidelines Illness and Injury Prevention

Federal Food, Drug, and Cosmetic Act By: Kaytlynn Martin Period 6

Professional Organizations

EDUCATE: A NESTcc Demonstration Project Regulatory Perspective

Linda M. Chatwin, Esq. RAC Business Manager, UL LLC

Opening an IND: Investigator Perspective

Safety Guidelines Illness and Injury Prevention

Left Atrial Appendage Occlusion for The Unmet Clinical Needs of Stroke Prevention in Nonvalvular Atrial Fibrillation David R. Holmes, MD, Mohamad Alkhouli,

Regulatory Perspective of the Use of EHRs in RCTs

Safety Guidelines Illness and Injury Prevention

Presentation transcript:

Appropriate Regulation of Adjunctive Devices: Embolic Protection Sadaf A. Toor, M.S. LT, U.S. Public Health Service Biomedical Engineer Peripheral Interventional Devices Branch Office of Device Evaluation Food and Drug Administration February 25, 2013

I/we have no real or apparent conflicts of interest to report. Sadaf A. Toor, M.S. I/we have no real or apparent conflicts of interest to report.

FAQs Regulatory Pathway? 510(k) or PMA? 510(k) with clinical data Will my submission go to Panel? Maybe. These are first of a kind devices, and 510(k)s can go to Panel. New questions of S&E? Quality/strength of data collected?

FAQs (cont.) Is a RCT needed? No, but there should be an appropriate control and data should be recent. Can I use OUS Data? Yes, some but not all. OUS patient population and medical practice should compare to US. What endpoints should we study? Include an assessment of both safety and effectiveness. 4

Safety and Effectiveness emboli caused by the device? risk for perforation, dissection Effectiveness: preventing stroke Imaging: DW-MRI Neurocognitive measurements for clinical sequelae Use an appropriate control 5

Pre-clinical Testing Risk-based analysis Coronary and Carotid EPD Guidance (2008) can be a good starting point geared towards filter and balloon type devices Not all testing may apply AND may not cover all testing necessary RISK ANALYSIS! 6

Seek FDA Feedback early Make use of the Pre-Submission Program as a tool for obtaining feedback It’s never too early to talk to us! 7

Helpful Resources Guidance: Coronary and Carotid Embolic Protection Devices (Issued: February 15, 2008) http://www.fda.gov/downloads/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm071217.pdf Draft Guidance: The Pre-Submission Program (Issued: July 13, 2012) http://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/GuidanceDocuments/ucm310375.htm 8

E-mail: Sadaf.Toor@fda.hhs.gov Questions? E-mail: Sadaf.Toor@fda.hhs.gov Thank you! 9